A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Eli Lilly and Company
- Study ID
- NCT01624259
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- LY2189265 — DRUGAdministered SC
- Liraglutide — DRUGAdministered SC
- Metformin — DRUG
Study Details
The purpose of the study is to assess the benefits and risks of once-weekly dulaglutide compared to once-daily liraglutide in participants with type 2 diabetes who have inadequate glycemic control on metformin.
Key Dates
- Start date
- Jun 30, 2012
- Status verified
- Oct 2014
- Primary completion
- Nov 30, 2013
- Completion
- Nov 30, 2013
Study Design
- Enrollment
- 599 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: 1.5 mg LY2189265LY2189265 (Dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), once weekly for 26 weeks Metformin: at least 1500 mg/day, oral, for 26 weeks
- Active Comparator: LiraglutideLiraglutide 0.6 mg, SC, once daily for 7 days, then titrated up to Liraglutide 1.2 mg, SC, once daily for 7 days, then titrated up to Liraglutide 1.8 mg, SC, once daily for 24 weeks Metformin: at least 1500 mg/day, oral, for 26 weeks
Primary Outcome Measure
Change From Baseline to 26 Weeks Endpoint in Glycosylated Hemoglobin (HbA1c) [ Time Frame: Baseline, 26 Weeks ]
Locations (18)
Find similar trials in Phoenix, AZ
By condition
By specialty
By research site
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.· Phoenix, AZFor additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.· Chino, CAFor additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.· Fresno, CAFor additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.· Los Angeles, CAFor additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.· Spring Valley, CAFor additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.· Fort Lauderdale, FL
Related Studies
- The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older AdultsRecruiting · AdventHealth Translational Research Institute · Orlando, Florida
- Mechanisms of Fatigability With DiabetesRecruiting · University of Michigan · Ann Arbor, Michigan
- Time Limited Eating in Adolescents With Type 2 Diabetes (KT2D)Recruiting · Children's Hospital Los Angeles · Los Angeles, California
- Effectiveness and Safety of the RIGHTEST Continuous Glucose Monitoring System for Blood Glucose Management in Persons With Diabetes MellitusNot Yet Recruiting · Bionime Corporation · Guntersville, Alabama